Strides Pharma Q1 FY27 Results: Consolidated Revenue at ₹1270 Crore, Profit at ₹165 Crore
Strides Pharma Science Limited reported Q1 FY27 results with consolidated revenue at ₹1270.30 crore and profit at ₹165.49 crore. Standalone profit was ₹72.93 crore. The company recorded an exceptional gain of ₹76.40 crore from diluting its stake in Pivot Path. A final dividend of ₹5 per share is proposed.
The announcement includes key financial performance indicators for the quarter, a significant exceptional gain, and a proposed dividend, all of which are material information for investors and can influence investment decisions.
The company reported positive financial results with increased revenue and profit, along with a proposed dividend and an exceptional gain, indicating a favorable financial performance.
Strides Pharma Science Limited announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the consolidated and standalone financial results today, July 31, 2026. The board meeting commenced at 10:30 hrs IST and concluded at 12:30 hrs IST.
Consolidated revenue from operations for the quarter stood at ₹12,702.97 million (₹1270.30 crore), with other income amounting to ₹48.90 million (₹4.89 crore), leading to a total income of ₹12,751.87 million (₹1275.19 crore). Total expenses were ₹11,325.93 million (₹1132.59 crore). Profit before exceptional items and tax was ₹1,377.04 million (₹137.70 crore). After accounting for exceptional items of ₹631.97 million (₹63.20 crore) and profit before tax of ₹1,996.16 million (₹199.62 crore), the profit for the period attributable to owners of the company was ₹1,654.93 million (₹165.49 crore).
Standalone revenue from operations for the quarter was ₹5,841.23 million (₹584.12 crore), with other income at ₹14.75 million (₹1.47 crore), resulting in a total income of ₹5,855.98 million (₹585.60 crore). Total expenses were ₹5,757.66 million (₹575.77 crore). Profit before exceptional items and tax was ₹83.57 million (₹8.36 crore). However, an exceptional item of ₹764.01 million (₹76.40 crore) was recorded, leading to a profit before tax of ₹847.58 million (₹84.76 crore). The profit for the period attributable to owners of the company was ₹729.28 million (₹72.93 crore).
Notably, the company reported an exceptional gain of ₹764.01 million (approx. ₹76.4 crore) on June 27, 2026, related to the dilution of its controlling stake in Pivot Path Private Limited, resulting in a loss of control and the retained interest being recognized as an investment in an associate. Additionally, the company proposed a final dividend of ₹5 per equity share, subject to shareholder approval at the Annual General Meeting.
What to do with a filing like this
Strides Pharma Science Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Strides Pharma Science Limited. Read the original for the full detail.